University of Cambridge receives Multi-million Dollar Funding for Clinical Trial using PharmaJet’s Needle-free System to Deliver Vaccine to Prevent COVID-19

GOLDEN, Colo. — October 27, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System will be used to deliver a vaccine against SARS-CoV-2 in a clinical trial. The vaccine developed by DIOSynVax, a spinoff company supported by the University of Cambridge in the UK, recently received multi-million dollar funding from the UK government to move forward with a clinical trial. Preparations for the clinical trial are well underway and the trial will begin as soon as possible.